Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma.
OBJECTIVE
To report the association of the development of a primary, cutaneous, anaplastic large-cell lymphoma after initiation of glatiramer acetate treatment of a patient with relapsing-remitting multiple sclerosis.


METHODS
Case report.


METHODS
Dermatology outpatient clinic. Patient A 33-year-old white woman developed an erythematous nodule on her leg 4 months after starting treatment with glatiramer acetate. Biopsy showed primary, cutaneous, anaplastic large-cell lymphoma. Further evaluation showed no systemic involvement. Intervention Radiation therapy induced a complete remission.


CONCLUSIONS
Several T-cell-mediated skin conditions have been associated with the use of glatiramer acetate, such as pseudolymphoma, drug eruptions, and erythema nodosum. We report the association of a T-cell malignancy with the use of glatiramer acetate.
Department of Dermatology, Scott and White Memorial Hospital, 2401 S 31st St, Temple, TX 76508, USA.
Monica M
MM
Madray
John F
JF
Greene
David F
DF
Butler
D000328:Adult; D015415:Biomarkers; D001706:Biopsy; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D017730:Ki-1 Antigen / Q000096:biosynthesis; D007866:Leg / Q000473:pathology*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy; D018365:Neoplasm, Residual; D010455:Peptides / Q000009:adverse effects*; D011878:Radiotherapy; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome
D015415:Biomarkers; D007166:Immunosuppressive Agents; D017730:Ki-1 Antigen; D010455:Peptides; D000068717:Glatiramer Acetate